FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
This article was originally published in The Pink Sheet Daily
FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.
You may also be interested in...
Success of review model for new molecular entities and novel biologics should bolster US FDA and industry's stance that Congress reauthorize the user fee program without tinkering with the negotiated agreement, which retains the 'Program' but builds in more flexibility.
The four-month review of Merck’s Keytruda for first-line lung cancer is a reminder of how quickly the agency has acted on the immune checkpoint inhibitors.
Oncology drug sponsors have gotten used to a “faster-than-Priority” timeline for breakthrough products. Now, FDA is outlining a formal process for its reviewers to use for any “Breakthrough” designated therapy with life-saving potential.